Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: a Multicentric, Phase II, MITO END-4 Trial

NCT07522697 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.

NCT NCT07522697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07522697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: a Multicentric, Phase II, MITO END-4 Trial
Lead sponsor
National Cancer Institute, Naples
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 31, 2026
Completion date
May 31, 2030
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer